|
|
Enron Mail |
Mime-Version: 1.0
Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-From: emaildelivery@businesswire.com X-To: TX-INDUSTRIAL-INFO-RES@businesswire.com X-cc: X-bcc: X-Folder: \PTHOMAS2 (Non-Privileged)\Thomas, Paul D.\Inbox X-Origin: Thomas-P X-FileName: PTHOMAS2 (Non-Privileged).pst Welcome to eMail News Delivery, a service from Business Wire. Here is your Industrial Information Resources Inc. news release. If you have received this in error please send a message to: eMailDelivery@businesswire.com with the following command in the body of the message: unsubscribe TX-INDUSTRIAL-INFO-RES If you have questions about this service, please contact your Business Wire Account Executive or service@businesswire.com BW2035 NOV 27,2001 2:00 PACIFIC 05:00 EASTERN ( BW)(TX-INDUSTRIAL-INFO-RES) Immunex Spending $500 Million on New Rhode Island Plant to Produce Enbrel, in an Advisory by Industrialinfo.com Business Editors & Health/Medical Writers HOUSTON--(BUSINESS WIRE)--Nov. 27, 2001--Researched by Industrialinfo.com (Industrial Information Resources Inc; Houston) The Immunex Corporation (Nasdaq:IMNX)(Seattle) is set to start construction on a fourth manufacturing plant for their very profitable arthritis therapy, Enbrel(R). Immunex enjoyed a third quarter 2001 net income of approximately $40 million, an increase of 26% over the same period last year. Immunex is working towards ensuring enough manufacturing capacity to support an anticipated $5 to $6 billion in Enbrel(R) sales over the next five years. Dubbed the "BioNext Project," the new facility is being engineered by Kvaerner Process (Bridgewater, N.J.), with Turner Construction (Dallas) handling construction management. The plant will house one of the largest bioreactors used in the industry, estimated to be 20,000 liters in capacity. There will also be a centralized utility area featuring water-for-injection (WFI), clean steam, and other central utility services. The project is adjacent to an existing facility that is currently being retrofitted to produce Enbrel(R) in an agreement with Wyeth-Ayerst Pharmaceuticals (Saint Davids, Pa.), another division of American Home Products Corporation (NYSE:AHP) (Madison, N.J.), which has 41% ownership of Immunex. AHP has agreed to sell Immunex the facility, which it purchased in 1999 specifically for the production of Enbrel(R). The new plant is expected to employ 350 people once construction is complete in 2005. The Immunex Corporation was founded in 1981. The biopharmaceutical company focuses on immune system science innovations, with Enbrel(R), their rheumatoid arthritis therapy, adding heavily to their 2000 revenues of $861.8 million and a net income of $154.4 million. Industrialinfo.com provides daily news related to the industrial market place including industry alerts and databases for the energy and industrial markets. For more information on trends and upcoming construction activities in the chemical and pharmaceutical industry as well as other industrial sectors send inquiries to chemicalsgroup@industrialinfo.com or visit us at www.industrialinfo.com. --30--AA/ho* CONTACT: Industrialinfo.com, Houston Trey Hamblet, 713/783-5147 KEYWORD: TEXAS NEW JERSEY PENNSYLVANIA WASHINGTON RHODE ISLAND INDUSTRY KEYWORD: BUILDING/CONSTRUCTION CHEMICALS/PLASTICS MANUFACTURING MEDICAL PHARMACEUTICAL SOURCE: Industrialinfo.com For the best viewing of the news releases please use the following email settings: Courier 10 point. -Notice of Copyright and General Disclaimer- © 2000 Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire`s members who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission. - Notice of Copyright and General Disclaimer -- © 1999 Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire`s members who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
|